With the massive size of the cholesterol-lowering drug market, these results beg the question: Could MK-0616 be the next hit ...

Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and ...

The extensive analysis of the market is based on key factors such as the historic and current market size, market share, market trends, competitive landscape, and growth opportunities. The report also ...

MarkNtel Advisors’ industry professionals present a comprehensive and professional study of the Hypercholesterolemia Market. The study is a perfect blend of quantitative and qualitative data tha ...

(Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, ...

Regeneron Pharmaceuticals Inc. (REGN) said that the U.S. Food and Drug Administration has approved Evkeeza (evinacumab-dgnb) to treat ...

The drug, MK-0616, was effective and well tolerated in patients with a variety of ASCVD risks. Phase III plans are now afoot.

This new article publication from Acta Pharmaceutica Sinica B, discusses the development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia.

Homozygous familial hypercholesterolemia occurs when two copies of the FH-causing genes are inherited, one from each parent, ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...

Pharmacodynamics of the immune response will be measured by LDL cholesterol levels, an established model of PCSK9 inhibition in hypercholesterolemia. “We’re excited to get this first-in-human ...